[Drug-drug interactions in urology]

Area of Science:

• Pharmacology
• Clinical Pharmacy
• Drug Safety

Context:

• Patients frequently use multiple urological and non-urological drugs concurrently.
• Concomitant medication use increases the risk of drug-drug interactions (DDIs).
• DDIs are a significant cause of adverse drug reactions.

Purpose:

• To explain the mechanisms and clinical significance of drug-drug interactions in patients on multiple medications.
• To highlight the importance of understanding pharmacodynamic and pharmacokinetic DDIs.

Summary:

• DDIs can be pharmacodynamic (e.g., anticholinergic effects, PDE5 inhibitors with nitrates) or pharmacokinetic (e.g., involving CYP3A4, CYP2D6 metabolism, or transporters).
• Enzyme inducers/inhibitors (e.g., CYP3A4) can alter drug concentrations, leading to outcomes like transplant rejection, nephrotoxicity, or contraindications (e.g., darifenacin with CYP3A4 inhibitors).

Impact:

• Knowledge of DDIs enables healthcare providers to anticipate and mitigate potential adverse drug events.
• Understanding DDIs improves patient safety and optimizes therapeutic outcomes in polypharmacy.
• This awareness is vital for managing complex medication regimens and preventing drug-related complications.